Semaglutide injection - Chia Tai Tianqing Pharmaceutical Group
Alternative Names: TQF-3510Latest Information Update: 28 Feb 2025
Price :
$50 *
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 24 Dec 2024 Preclinical trials in Obesity in China (Parenteral), prior to December 2024
- 18 Dec 2024 Chia Tai Tianqing Pharmaceutical plans a phase III trial for Obesity in China in March 2025 (Parenteral) (NCT06738979)